Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

131.81 +0.63 (+0.48%)
Streaming Delayed Price Updated: 12:09 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
US Supreme Court Reportedly Upholds Part Of Obamacare That Guarantees Health Insurers Cover Preventive Care
The Obamacare law requires health insurers to provide preventive care, including cancer screenings and HIV prevention medication, at no cost to patients. 
Via Stocktwits
Topics Government Lawsuit Religion
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
Major Sector ETFs Wildcard: Biotechnology
On the weekly chart, IBB is breaking under the 200-week moving average. 
Via Talk Markets
Topics ETFs
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new... 
Via Benzinga
Topics Government World Trade
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
The Major Sector ETFs Got Their Story
XRT has more work to do. At best, the consumer sector is trying to bottom. At worst, this is a rally into resistance. 
Via Talk Markets
Topics ETFs
Major Sector ETFs Break For Easter
SMH holds steadfast above the 200-WMA even in the face of the tariffs and chip ban to China. 
Via Talk Markets
Topics Cryptocurrencies ETFs World Trade
RFK Jr.'s Massive Federal Health Workforce Cut Could Take 'Decades To Rebuild,' Warn Experts: 'We Cannot Accurately Assess Whether We Are Truly Making America Healthier'
Experts raise alarms about Health Secretary Robert F. Kennedy Jr's decision to layoff tens of thousands of federal workers, disrupting critical health data collection and research efforts. 
Via Benzinga
Topics Workforce
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger
Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma. 
Via Stocktwits
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?
The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss. 
Via Stocktwits
Can Buying In The Broader Market Pick Up Steam?
Both SPY and QQQ must get back over and close above their 50-WMA to convince bulls the move Friday, while a reversal in the works, is not just a dead cat bounce. 
Via Talk Markets
Topics ETFs
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros. 
Via Stocktwits
Healthcare Sector Trying To Bounce Back
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector. 
Via Talk Markets
Topics ETFs Stocks / Equities
March Came In Like A Lion - Key Sectors Are Looking For A Lamb
Looking at the monthly chart, XRT now sits back in economic contraction, or below the 23-month moving average. 
Via Talk Markets
Topics ETFs
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027. 
Via Stocktwits
Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars?
Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as... 
Via Talk Markets
Topics ETFs Stocks / Equities
Biotech Rally Coming In Weeks Ahead?
Large cap biopharma and MedTech stocks are leading the healthcare sector higher. 
Via Talk Markets
Topics ETFs Stocks / Equities
Semiconductors Fail A Key Support Level - And More
It has been 2 years and 2 months since the ETF for Semiconductors SMH has traded below the 50-week moving average. 
Via Talk Markets
Topics ETFs
4 Sectors That Thrive When Inflation Runs Hot
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
Via MarketBeat
Topics Economy World Trade
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?
The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder. 
Via Stocktwits
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
The Inside Sectors Of The Economy Flash Warning
Zooming out to the weekly chart of TLT, we see a double bottom in play from the lows in October 2023 and January 2025. 
Via Talk Markets
Topics Commodities ETFs Economy
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?
Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results. 
Via Stocktwits
Biotech Stocks Had A Good Week Despite Crosscurrents
It’s too early to account for the rally but in general one can say that there is a lot of speculation from both the retail side and hedge funds. 
Via Talk Markets
Topics ETFs Stocks / Equities
Do The Major Sector ETFs Love High Flying Stocks?
The major sector ETFs remain muted. Nothing screams wildly bullish or horribly bearish in the weekly charts. 
Via Talk Markets
Topics Cryptocurrencies ETFs
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp. 
Via Stocktwits
Price Action Disputes Most Macro Narratives
Do you believe the economy is heading towards inflation? What about a recession? Are gold prices sending a warning? Read on for the answer. 
Via Talk Markets
Topics Economy Stocks / Equities
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.